AroCell patent approved in Japan - Arocell TK 210 ELISA

AroCell AB (publ) announced today that the patent no 6715770 and titled “Monoclonal anti-TK1 antibodies” is granted by the Japanese Patent Office.

The patent application relates to AroCell’s proprietary monoclonal antibodies used for determining the Thymidine kinase 1 concentration in serum samples. These antibodies are used in the AroCell TK 210 ELISA kit.

“We are delighted that this patent has been granted by the Japanese Patent Office. This reinforces our patent position and increases AroCell’s attractiveness as a business partner in Asia.” says Michael Brobjer, CEO AroCell.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com